June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Retrospective cohort analysis of patients with geographic atrophy (GA) secondary to age-related macular degeneration followed for 3 years in clinical practice.
Author Affiliations & Notes
  • M. Ali Ali Khan
    Retina Service, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Ehsan Rahimy
    Retina Division, Palo Alto Medical Foundation, Palo Alto, California, United States
  • Allen C Ho
    Retina Service, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Ryan Corley
    Verana Health, California, United States
  • Mark Gallivan
    Verana Health, California, United States
  • Daniel Jones
    Apellis Pharmaceuticals Inc, Crestwood, Kentucky, United States
  • Ramiro Ribeiro
    Apellis Pharmaceuticals Inc, Crestwood, Kentucky, United States
  • Theodore Leng
    Department of Ophthalmology, Stanford University, Stanford, California, United States
    Verana Health, California, United States
  • Nancy M Holekamp
    Pepose Vision Institute, Chesterfield, Missouri, United States
  • Footnotes
    Commercial Relationships   M. Ali Khan Genentech, Apellis, Allergan, Code C (Consultant/Contractor), Regeneron, Code F (Financial Support); Ehsan Rahimy Apellis Pharmaceuticals, Code C (Consultant/Contractor); Allen Ho Apellis Pharmaceuticals, Code C (Consultant/Contractor); Ryan Corley Verana Health, Code E (Employment); Mark Gallivan Verana Health, Code E (Employment); Daniel Jones Apellis Pharmaceuticals, Code E (Employment); Ramiro Ribeiro Apellis Pharmaceuticals, Code E (Employment); Theodore Leng Apellis Pharmaceuticals, Code C (Consultant/Contractor), Verana Health, Code F (Financial Support); Nancy Holekamp Apellis Pharmaceuticals, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 300 – F0103. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Ali Ali Khan, Ehsan Rahimy, Allen C Ho, Ryan Corley, Mark Gallivan, Daniel Jones, Ramiro Ribeiro, Theodore Leng, Nancy M Holekamp; Retrospective cohort analysis of patients with geographic atrophy (GA) secondary to age-related macular degeneration followed for 3 years in clinical practice.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):300 – F0103.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report results from a retrospective analysis of clinical data, evaluating disease progression of patients with GA in 1 eye and either GA or choroidal neovascularization (CNV) in the other eye, over 3 years.

Methods : Patients (125,743) with GA in ≥1 eye were identified from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) from January 2016 to March 2017. Patients were excluded if they had a history of CNV or active CNV in the study eye, a history of any other retinal condition, or <36 months of follow-up. Patients were grouped by fellow eye status: Cohort 1, GA:GA; Cohort 2, GA:CNV (study eye GA, fellow eye CNV). Subgroups were classified by lesion location: nonsubfoveal (NSF) or subfoveal. Main outcomes were study and fellow eye disease progression including visual acuity (VA) over 3 years.

Results : Patients (36,817) met the inclusion criteria: Cohort 1: 21,789 (59.27%); Cohort 2: 14,976 (40.73%). In the GA:GA Cohort, NSF study eyes had a better mean VA at baseline (67.37 letters) than subfoveal eyes (62.33 letters). Mean 3-year VA changes from baseline were comparable for NSF (−10.38) and subfoveal (−9.31 letters) study eyes. Similar trends were observed in the GA:CNV Cohort: NSF study eyes had a better mean VA at baseline (65.80 letters) than subfoveal eyes (46.80 letters). Mean 3-year VA changes from baseline were similar for NSF (−8.53 letters) and subfoveal (−8.26 letters) study eyes. In GA:GA and GA:CNV Cohorts, NSF study eyes with a baseline VA of ≥20/40 lost a mean of −10.33 and −8.19 letters and subfoveal eyes lost a mean of −8.59 and −9.96 letters over 3 years, respectively (Figure). NSF study eyes with a baseline VA of <20/40 and ≥20/100 in GA:GA and GA:CNV Cohorts lost a mean of −12.09 and −11.44 letters vs −13.57 and −12.89 letters, respectively in subfoveal eyes over 3 years (Figure).

Conclusions : GA caused substantial disease burden in this retrospective study of a large real-world database. Eyes with GA lost significant vision over a 3-year period, consistent with trends in the previously reported 2-year analysis. The rate of vision loss was numerically similar regardless of whether lesions were NSF or subfoveal at baseline. Eyes with good vision at baseline lost more letters over 3 years compared to eyes with poor vision.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Figure. Mean study eye VA changes from baseline over time.

Figure. Mean study eye VA changes from baseline over time.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×